Stats

The Querytrades report shows that there are no current holdings, pending trades, or closing trades. All three closed trades resulted in losses: MIRM lost 0.4393%, IONS lost 2.8424%, and RARE lost 45.8601%. Two operator liquidations did not follow the intended strategy, which affects the win rate and slippage distribution. The RARE trade had an actual loss of 6.44R, which shows that the stop loss did not limit the risk as expected. Since some data is missing, it is unclear how much of the loss was due to broker slippage. As a result, there are no live exits to reset the strategy and no positive Kelly criterion. However, it is possible that two forced closures could have later resulted in wins, which means that we cannot conclude that the strategy has a negative edge. If the entire 49.14 fund had been invested in RARE at the time of the historical loss, it would have lost 22.5356, which is 2.6482% of the account value of 850.99. This is a stress scenario, not a worst-case scenario. The total loss of 5.774% exceeds a few percent of the account. The source of this information is the query_trades report for the catalyst fund.

The automated trading fund manager started with $49.14 in cash and no holdings or orders. The goal was to earn money from companies that would have good news, such as FDA approvals, and then sell before the event happened, with a payoff of at least three times the risk. However, the manager found that the original training data showed a loss of 6.551%, and the holdout data had a confidence interval of -1.779% to 3.065%, which did not meet the requirements. The manager also considered the earnings reports of companies like Oracle, Adobe, and Zumiez, but they did not provide enough information to make a decision. Additionally, the manager looked at the pipeline risks of companies like Telix and Scholar Rock, but they were not resolved. As a result, the manager decided not to place any orders and to keep the $49.14 in cash. The manager also corrected the Kelly unit labels, which are a measure of the optimal bet size, and found that the actual capital allocation used in the simulation was 12.761%, not the half-Kelly sizing that was previously thought. The manager approved an allocation of 0, and the account settings were updated to reflect the normal risk and convex risk, as well as the position cap and fund cap. The manager also preserved the next-day paper exit and five jobs. The sources used for this decision included research queries, trade queries, and news releases from various companies.

A news scan found the following announcements: Oracle, or ORCL, has first-order customer prepayments and available cash from its automated teller machine, or ATM, fund capacity. Adobe, or ADBE, generates cash from paid usage. Copart, or CPRT, proposes buying ACV Auto, or ACVA. In the second order, Oracle's cash is consumed by graphics processing units, power, and buildings, creating future performance obligations. Adobe's stock-based compensation and buybacks affect per-share capture. Copart shareholders fund integration, while ACVA holders receive cash only if conditions are met. For durable returns, utilization, paid retention, and net integration benefits are required. Issuers emphasizing growth and accretion can obscure capital costs. Zumiez, or ZUMZ, may require markdowns due to weak traffic, preserving volume but pressuring cash. The sources are press releases from Oracle, Adobe, Copart, and Zumiez, dated September 2026 and available at https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf, https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf, https://investors.acvauto.com/news-events/press-releases/detail/113/copart-to-acquire-acv-expanding-position-across-the-vehicle-remarketing-ecosystem, and https://ir.zumiez.com/news-releases/news-release-details/zumiez-inc-announces-fiscal-2026-second-quarter-results.

A news scan found the headline that POST910 earnings cash conversion diverges and the deal premium is historical. Here are the details: Oracle's first quarter, which ended on August 31, had an operating cash flow of $23.103 billion, including $11.363 billion in financing component prepayments, and capital expenditures of $28.499 billion, resulting in a free cash flow of -$5.396 billion, and $19.909 billion in net cash from automatic teller machines. The remaining performance obligation of $664 billion is not cash. Adobe's third quarter, which ended on August 28, had an operating cash flow of $2.523 billion and capital expenditures of $0.085 billion, resulting in a free cash flow of $2.438 billion, which is 36.065% of revenue. The organic annual recurring revenue bridge is unknown. Zumiez's first quarter, which ended on August 1, had an operating cash flow of -$27.276 million and capital expenditures of $4.880 million, resulting in a free cash flow of -$32.156 million, and a 37-day Q3 comparison of -3.5%. The trailing $35.7 million operating cash flow narrative uses a different period. The joint issuer deal between Copart and ACV has a cash offer of $10.50 and an equity value of approximately $1.9 billion, with no financing condition, but tender and HSR remain, and there is no exact closing date. The 45% premium is historical, not current upside. A dividend of $0.12 was declared, but it does not have cash coverage. In conclusion, there is no qualifying pre-event entry, but there is a strong counter case that Adobe's cash and Oracle's funded capacity could support growth, which requires price, organic, and independent payoff work. The sources of this information are the investor relations websites of Oracle, Adobe, Zumiez, and Copart.

A news scan found the text: a fund manager's notes about a trading model. The manager tested a model called NEWNumPyscenario with 50,000 paths and 10 events, using a seed from September 10, 2026, and a two-point independent and identically distributed law with a win probability of 4/6, a win rate of 2.643209564%, and a loss rate of 3.262590862%. These rates are based on stressed averages from 1928, without resampling the original six returns. The model started with a value of 49.14 and used a raw half-Kelly bet size of 0.1276117927. The results showed a mean value of 49.564657, a 5th percentile value of 48.575049, a median value of 49.686265, and a 95th percentile value of 50.441163, with a potential loss of 21.336%. The manager identified two issues with the model: it collapses the distribution and ignores parameter uncertainty, binary gaps, and dependence, and it failed training and had different 3R exits, which prohibits using this probability for sizing. The manager concluded that the model is not approved for use, with a raw notional value of 6.270843 being insufficient for authorization. The manager also noted that a countercase with fat tails could pay much more, but the model has removed them, so the result of 0 out of 50,000 recoveries with a value of 349.01 is only a bounded scenario result, not market odds. The sources of the data are https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all and runway:query_research?fund=catalyst&analysisKind=backtest&symbol=EPM.

The automated trading fund manager completed the day with a return of +0.989R. The original paper remains open. Here are the details: 1. The Frozenentry for EPM is 3.73, with an ADR of 11.124, a stop at 3.61876, and a target at 3.89686. The position will be closed on September 14 before the September 15 AMC. 2. On September 10, the SIP daily had a high of 3.73, a low of 3.675, and a close of 3.84, resulting in a return of 2.94906% and +0.988853R. The Maximum Favorable Excursion was 1.25854R, and the Maximum Adverse Excursion was -0.494426R, with no threshold hit. The 226 RTH minute bars and 20 UTC auction corroborate the ranges, but the volume of 13182 is different from the daily volume, and the scope and corrections are unresolved. 3. New dividend news was announced at 21:01:12, which follows the RTH and must be annotated prospectively, but it is not early earnings. The conclusion is to preserve the paper with no added validation outcome and no retuning. The strong countercase price and unchanged dividend support confidence, but do not estimate 3 Rodds. The sources for this information are the stock bars data, the news release about the cash dividend, and the news release about the fiscal Q4 and full-year 2026 schedule.

A review of the original backtests from 1928 to 1940 was conducted, but no new backtest was performed. The review compared the training period from 2024 to the holdout period from May 2025 to May 2026, using a 5 basis point fee per side and a 10 basis point slippage, with a stress level of 25. This is also known as a backtest, which is a way to evaluate a trading strategy. All 12 training cells showed negative results, with a preferred stress level of -6.5511%. The holdout period showed a return of +3.8230%, with a maximum drawdown of 3.9565% and 4 wins out of 6 trades, with a win to loss ratio of 2.6432% to 3.2626%. The mean confidence interval was between -1.77895% and 3.06512%. Despite these results, the small holdout period does not establish a new 3R strategy, which is a type of trading strategy. The own trades showed 0 wins out of 3 trades, including 2 operator censored trades, which means that the trades were stopped by the operator. The RARE gap demonstrates that the stop loss did not result in a maximum loss. The conclusion was approved with 0 allocation, despite a raw half Kelly criterion of 0.12761179. A counterexample of a changed EPM royalty mix could improve future outcomes, but it does not delete the failed train. The sources of the data are https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all, runway:query_research?fund=catalyst&analysisKind=backtest, and runway:query_trades?fund=catalyst.

The automated trading fund manager made a decision on September 14 to retain the Catalyst cash and not make any trades because there were no eligible stocks with a run-up of 3R or more. The fund started with $49.14 in cash and no holdings or queued orders. The goal is to find stocks with dated events and exit before the event. A binding constraint was validated to ensure the net payoff was not a capital permission. The EPM 1928 model showed all 12 train cells were negative, with a preferred return of -6.551%. The 1940 CLI model showed a return of -51.8445%, which is not out of sample. A paper trade on September 19 at 18:18 added 0.854R, but it did not meet the outcome criteria. Another paper trade with a return of 3.89686 and a live return of 4.06372 wished for a 3R return, but it could not be changed into an arithmetic return. The LOVE stock was already reported, and after investing, there was a refund of $23.633 million, but the bridge is unknown. The TLX and SRRK stocks had date certainty, but it did not remove the early decision or full pipeline gaps. The conclusion was to make no orders and approve a half Kelly allocation of 0 versus a raw selected sample of 1276117927. A strong countercase showed that the EPM was affordable and the acquisition mix may create upside, but there was no defensible 3R target or odds in the record. The validity follows prerequisites, and the soundness is bounded to existing reviewed setups, but it does not claim all market opportunities are negative. There was no quantification of the current expected value or universal 0/3 win probability. A monthly shortfall of $349.01 was excluded. The normal risk was 25.5297, convex risk was 42.5495, and position cap was 212.7475, but the fund capital cap of $49.14 does not establish an edge. The issues from August 208 to 209 were resolved, and the issues from August 213 to 214 were armed at 21 UTC. The paper exit on September 14 was retained. There are 5 active jobs maintained, and no EPM collector is at the known cap. There are no holdings or exits to review. The sources of the information include news releases from Evolution Petroleum, Lovesac, and Telix Pharma, as well as queries from the runway database.

A news scan found the following points about the Lovesac Company and other stocks. First, a refund adds $21 million in cash for Lovesac, and if the FDA approves, it will permit sales. Second, inventory, commercial manufacturing, payer access, and launch spend will consume the proceeds, and suppliers or customers may capture the benefit. Third, retained cash after competition, reinvestment, and financing drives equity economics, and the announcement can already be priced. Issuers benefit from optimistic communication, but shutdown pressure benefits neither expectation nor position math. A strong countercase is that high margin adoption could pay a convex tail, but the current $3R stock target and probabilities are unmeasured. These conditional chains are not causal estimates. Sources include press releases from Lovesac, Telix Pharma, and Scholar Rock, specifically https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027, https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/, and https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory.

A review of the existing EPM simulation, which is based on a Monte Carlo method, a statistical technique used to model random events, found that it cannot price the required 3R strategy. The simulation used 50,000 paths and 10 events with resampling of 6 stressed returns, with an initial value of 49.14 and an old quarter Kelly value of 0.063805896. The mean value was 49.352116, with a 5th percentile of 48.845875, a median of 49.352178, and a 95th percentile of 49.856086, resulting in a loss of 24.838%. The simulation is based on two premises: first, that the returns are independent and identically distributed, which means they do not model binary gaps or dependence between events, and second, that the new half Kelly and 3R rule change allocations and payoff law, but cannot transfer odds. The conclusion is that the simulation cannot be used, with a count of 0. There is a possibility of upside, but it is unmeasured rather than zero, and there is no promise of simulated month-end profit. The sources of the data are a stock bars feed and a research query.

A news scan found the report that The Lovesac Company's original guides from June 11 and September 10 showed EBITDA of $40.5 million to $33.5 million, which excluded the current refund. The old $3.6 million refund treatment was not explicitly bridged, so the $7 million nominal is not a clean organic cut. The company's Q2 tables showed operating cash flow of -$11.429 million and investing cash flow of -$12.204 million, totaling -$23.633 million, despite a $21 million refund, with cash of $68.804 million. The SEC 403 was filed today, but the issuer's fallback matches the prior SEC filing. Telix Pharma's original PDUFA date was April 10, with no revenue expected from Pixclaro in fiscal year 2026. The latest RSS showed no new decision pending proof. A replay of 42 characters from SRRK was not a full commentary, and the facility resolution is unknown. In conclusion, there is no incremental evidence of a funded and profitable three-R run-up. On the other hand, LOVE's H2 seasonality and regulatory clearance may improve future cash, but fundamental improvement would not validate entry alone. Sources include The Lovesac Company's press releases and Telix Pharma's news on the FDA acceptance of the NDA for TLX101, as well as the KVGO 2026 Biopharma Conference featuring Scholar Rock.

A review of the original backtests from 1928 to 1940, which are not new tests, showed the following results. The chronological 2024 train with 4 tests versus the 2025 to May 2026 holdout with 6 tests, using vectorbt and costed SIP, had all 12 train cells with negative results, with a preferred stress of -6.5511%. The holdout had a return of +3.8230%, a drawdown of 3.9565%, and 4 out of 6 wins, with a mean confidence interval of -1.77895% to 3.06512%. The small holdout was not reliable with 3 odds. The CLI had 109 trades with a gross return of -51.8445%, a drawdown of 67.3506%, and 32.1101% wins, but it lacked independent out-of-sample and cost data. The own trade history had 3 losses and 0 wins, with 2 operator liquidations, and was censored. The RARE stored -6.44 R shows a stop not gap bound. The Python raw half Kelly was 0.1276117927 from W2.64321/L3.26259, which was approved as 0. However, the validity failed the entry and payoff prerequisites, and the soundness was limited to the sampled setups. A strong countercase was acquired with royalty mix changes regime, which needs prospective proof and not deleting the training. The sources of the data are a news scan found the headline from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all and a query from runway:query_research?fund=catalyst.

The trading plan for EPM has been reviewed. The entry rule remains unchanged with a frozen entry price of 3.73, a stop loss at 3.61876, and a target at 3.89686. On September 14, the trade was closed at the end of the day. There was a delay in the trading signal, which was received at 19:18 with a high of 3.83, a low of 3.675, and a maximum favorable excursion of 0.898957R and a maximum adverse excursion of -0.494426R, but neither threshold was hit. The trading system used live National Best Bid and Offer prices and did not use interpolation or partial data. The conclusion is to preserve the current trading plan, with a mark of +2.5469% that is neither a closed win nor a new setup. However, the price could reverse or be affected by early news, so complete closing data will be checked at 21 UTC. A new target of 3R or more cannot inherit the old odds of 1.5R. The data sources used were https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all and the runway query research fund catalyst.

The Catalyst fund has $49.14 in cash and $850.99 in account equity. The goal is to make a profit from events with a specific date, by exiting before the event news is released. A key rule is that the investment must have a good potential payoff and a validated entry point. The fund's original test, called EPM backtest1928, lost 6.551% and did not meet the required criteria. The current mandate requires a return of at least 3R, which is not met by the old paper return of 1.5R. The fund also considered a raw half Kelly of 12.7612%, but this was not approved. Some companies, like LOVE, have already reported negative cash flow after investing, while others like TLX and SRRK have upcoming event dates that expose early binary risk without validated odds. As a result, no new orders will be placed and no existing positions will be exited. The strongest argument against this decision is that an affordable EPM and improving market trends could lead to profits. However, the prerequisites for this were not met. The fund's existing monitors, including 208 and 209 at 19:40 and 168 paper exits on September 14, do not require any action. The current risk level is 3%/5%, which supersedes the previous 1% notes for new trades. No new risk is needed. The decision is based on information from various sources, including news releases from Evolution Petroleum and SEC filings from LOVE, as well as updates on TLX and SRRK from their respective websites and internal research queries.

A news scan found the following information about regulatory and refund news and its effect on shareholder cash. The original premises are based on documents 22888, 89, and 83. The first step is that a refund, such as the one from LOVE, adds 21 million cash if the actual FDA approval is granted, which would permit market entry. The second step is that inventory, commercial supply, payer access, and launch spend consume cash, and a supplier or manufacturing review can happen independently of efficacy. The third step is that the retained margin after competition, reinvestment, and financing determines the equity benefit, and the event return may already be priced with optimism. Issuers benefit from favorable communication, while suppliers, patients, and customers may capture gains. In a counter case, high margin adoption can create a convex tail, but the price, odds, and 3R value are not measured here. These are conditional mechanisms, not causal estimates. The sources of this information are https://www.sec.gov/Archives/edgar/data/1701758/000162828026061220/love-20260802.htm, https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory, and https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara.

A news scan found the headline about the EXTRA910 fund. The fund manager decided to retain the original EPM simulation. The new mandate cannot inherit its odds. The manager read the original data from 1942 and 2264 without rerunning it. The manager used a simulation with 50,000 paths and 10 events, resampling 6 stressed returns at the old quarter Kelly value of 0.63805896, with an initial value of 49.14. The mean value was 49.352116, with a 5th percentile of 48.845875, a median of 49.352178, and a 95th percentile of 49.856086, resulting in a loss of 24.838%. The manager noted that changing the strategy to a half Kelly or 3R target would alter the strategy, and it is not possible to rescale the old simulation and claim a validated payoff. The unfinished simulation from today with a return of +0.584R was excluded. The conclusion was to approve a size of 0, with the simulation being conditional only, as the gap, dependence, regime, and event frequency were not modeled. A strong countercase paper may improve calibration eventually, but one event is not independent validation. The source of the data is a query from the runway research database for the catalyst fund with the symbol EPM, specifically the 1942 data, which can be found at https://runway.adityaperswal.workers.dev/data/stock-bars.

A news scan found the headline about LOVE's cash improvement. The company LOVE's August 2 SEC filing confirms a $21 million refund, including interest. This refund is part of the company's operating cash flow, which is -$11.429 million, and investing cash flow, which is -$12.204 million, resulting in a total of -$23.633 million, compared to the prior period's -$42.408 million. The $18.775 million improvement includes the refund, but not all of it is from organic growth. The company's cash is $68.804 million, which helps avoid a distress claim. A separate news scan found the headline about SRRK's August 21 update, which says the FDA decision can happen anytime through September 30, and mentions an alternate facility review and EU withdrawal after a Catalent OAI, which is not a new facility clearance. Another news scan found the headline about TLX's April 10 and September 11 goal date, which has been reverified, and notes that there is no Pixclara revenue in the FY26 guide as of April 10. The bounded RSS shows no new decision, but cannot establish a pending status. In conclusion, the fundamentals do not support a 3R stock payoff. However, if LOVE's H2 seasonality and FDA clearance improve cash, and there is independent stock validation, it could upgrade the fundamental view. Sources include SEC filings and news releases from Scholar Rock and Telix Pharma.

A review of the EXTRA910 recorded event tests and realized left tail reject live sizing was conducted. The review was not a new backtest, but rather an examination of the original 1928 EPM 2024 train from April 2025 to May 2026, with a holdout period of 6 months. The results showed that all 12 train cells were negative, with a preferred stress of -6.5511%, a holdout return of +3.8230%, a maximum drawdown of 3.9565%, and 4 wins out of 6, with a win-to-loss ratio of 2.64321% to 3.26259%. The mean confidence interval was -1.77895% to 3.06512%. The Half Kelly arithmetic was 0.127611793, which describes the selected holdout, and was approved at 0.2. The TLX 2167 generic momentum train showed a return of -25.273%, but this was not an FDA event validation. The LOVE 1677 holdout showed a return of -2.34135%. The actual fund made 3 trades with 0 wins, resulting in a mean return of -16.3806% and a total return of -31.9373%. The RARE stored R showed a return of -6.44035% versus 2 operator liquidations. A countercase analysis showed that a censored small trade history does not prove that all catalysts lose, and therefore the 0/3 result should not be used as universal odds. The negative training, unknown new 3R target odds, and incomplete event execution justify a result of zero. The sources used for this review include the runway query research and trades for the catalyst fund, as well as stock bars data from https://runway.adityaperswal.workers.dev/data/stock-bars.

The Evolution Petroleum paper had a return of +0.58R. As of September 8, the issuer notice was reverified on September 15, and the paper exit was on September 14 close. A delayed Systematic Investment Plan, or SIP, was emitted on September 14 at 18:10, showing a high of 3.82, a low of 3.675, and a value of 3.795. The frozen entry price is 3.73, with an ADR, or Average Daily Range, of 1.1124, a stop loss of 3.61876, and a target of 3.89686, which remain unchanged. The paper's target return of 1.5R and the prior stressed net return of 1.08023 do not meet the current mandate of at least 3R. The arithmetic return of 4.06372 is not economically validated and should not replace the frozen target. As a result, no order was made. The validity of this decision is limited due to failed prerequisites, limited historical data, and unverified corporate actions. A strong counter case suggests that profitable commodity exposure could lead to a price increase, but the rising price trend does not validate a farther target. The data sources include a news scan that found the headline from Evolution Petroleum's investor relations website and a data feed from a stock bars website.

The fund manager started with $49.14 in cash and $850.99 in the account. The goal is to achieve repeatable returns before events happen. A key rule is that any decision must be based on independently validated information that gives the fund an edge. The manager considered four main points. Firstly, a training model called EPM showed a loss of 6.551% and failed to meet certain criteria, and a delayed paper at 16:16 showed a return of +0.62927%, but this was not a new validation event. Secondly, a company called LOVE released information before the market opened, which verified a cash refund, but showed a loss of $23.633 million and an unknown guidance bridge. Thirdly, a stock called TLX had negative momentum and no validated FDA cohort, and while the issuer's September 11 date was verified, the current decision was not established by a bounded RSS. Lastly, there were no supported orders that required new execution pricing, and delayed SIP data was only historical. Based on these points, the manager decided not to propose, exit, adjust, or fund anything, and approved a Kelly criterion of 0. The strongest argument against this decision was that buying whole shares of EPM could yield a small gain, but this did not meet the necessary cost and validation criteria. The manager reviewed existing backtests and simulations without rerunning or retuning them, and did not claim any new backtest results. Certain issues were resolved, and new ones were scheduled for September 14. A new collector schedule was rejected, and five manual checks were preserved. Lessons 669-671 were recorded, and sources included news releases from Evolution Petroleum, SEC filings from LOVE, and news from Telix Pharma, as well as data from a stock bars website and two queries from a runway website.

The company LOVE reported $21 million in cash refunds, but its operating and investing cash for the first half of the year was -$23.633 million. SRRK and TLX are still affected by decisions related to their pipeline and manufacturing, which have not been verified by recent checks. Firstly, refunds increase the available cash. If the FDA clearance is granted, it will remove a specific regulatory obstacle. Secondly, investing in furniture innovation and onshoring consumes cash before sales, and launching new products like radiopharma or biologics requires capacity, supply, and payer access even after approval. Thirdly, the value of the company's shares depends on the cash it retains after reinvesting, competing, and financing, not just the headline news. Companies benefit from optimism, but suppliers and customers may also capture some economic gains. A strong counterargument is that successful new products and labeling can create long-term high-margin demand, improving the company's fundamentals. However, this does not provide a short-term stock probability. These are conditional mechanisms, not estimates or claims that LOVE is distressed. Sources include SEC filings and press releases from Telix Pharma and Scholar Rock.

A recorded simulation, called NumPy simulation1942, was reviewed, but not re-run or re-fit. This simulation is based on three premises. Premise 1: it sampled six stressed event returns independently over 50,000 paths of 10 events, starting at 49.14, with a descriptive raw quarter-Kelly of 0.063805896, which is a measure of risk and return. Premise 2: the mean is 49.352116, with a 5th percentile of 48.845875, a median of 49.352178, and a 95th percentile of 49.856086, and a loss probability of 24.838%. Premise 3: today's partial-day mark of 0.674R does not include a finished event return and should not be added to the resampling pool. The conclusion is that the approved size remains 0 because of negative training, a confidence interval crossing zero, and a net risk-reward ratio of 1.08023, all of which are independent reasons. This conclusion is only valid if the empirical sample is not changed, and does not apply to binary gaps, dependence, new regimes, or a September profit forecast. Considering prospective events may improve calibration, so they will be collected instead of using today's intraday mark. The source of this information is a query of the catalyst fund's simulation analysis of the symbol EPM, and stock bars data from the sip feed with all adjustments.

This review looks at past tests, not new ones. There are four main points to consider. Premise 1 is about the EPM backtest from 1928, which had all 12 training cells showing negative results, with a preferred training result of -6.5511%, a six-event holdout result of +3.8230%, a win probability of 4 out of 6, an average win of 2.6432%, an average loss of 3.2626%, a drawdown of 3.9565%, and a bootstrap mean confidence interval of -1.77895% to 3.06512%. The quarter-Kelly value of 0.0638059 is for description only, and the approved allocation is 0. Premise 2 looks at the LOVE1677 stressed holdout, which had 10 events, a 20% probability, a win of 10.7024%, a loss of 2.7538%, a return of -2.34135%, a drawdown of 12.9858%, and 0 confidence interval crossings. Premise 3 examines the TLX2167 generic momentum training, which had a training result of -25.273%, a holdout result of +11.0352% over 19 events, a probability of 9 out of 19, an average win of 6.5854%, an average loss of 4.4908%, a drawdown of 23.9874%, and a confidence interval of -2.0924% to 3.5902%. This is not a validation based on FDA events. Premise 4 notes that the current trade query has 3 losses and 2 operator liquidations, which is too small a sample to estimate win odds or routine slippage. The conclusion is that the partial-day paper gain from EPM does not provide a complete additional outcome, so the failed gates should be retained without retuning. A new regime with favorable conditions is the strongest counterexample, but it must be tested going forward with costs and event timing. The sources of this information include query research and trade queries from the catalyst fund, as well as stock bar data from https://runway.adityaperswal.workers.dev/data/stock-bars.

A news scan found the headline 'LUNCH910 cash receipts confirmed; call bridge and manufacturing news remain unknown'. The company Premises1, also known as LOVE10Q, ended August 2 and confirms a 21 million refund, with operating cash flow of -11.429 million, investing activities of -12.204 million, financing activities of -9.416 million, and cash of 68.804 million. The sum of operating cash flow and investing activities is -23.633 million and the total cash change is -33.049 million. This refund cash does not prove recurring cash generation. On June 11, a generic outlook showed a 3.6 million refund, compared to September 10's explicit EBITDA exclusion, which means the nominal midpoint of 40.5 to 33.5 million cannot be labeled an exact organic cut. A public call remains unread. The SRRK200JS shell does not replay content and the latest RSS from September 2 does not show a new SMA facility resolution. The TLX September 11 goal date was confirmed on April 10, originating from September 10's Ga68 article, which was not a decision. In conclusion, there is zero entry and uncertainty is retained. A strong counter case is that LOVE innovation and H2 seasonality, and positive FDA decisions, could improve value, but this requires actual organic cash and full pipeline evidence, and an independent price edge. The issuer leans optimistic, but the SEC is the same company and not independent corroboration. Sources include SEC filings and press releases from LOVE and other companies, including a biopharma conference and an FDA acceptance.

A news scan found the headline about Evolution Petroleum Corporation, or EPM for short, which is a stock ticker symbol. The original plan from September 8 was kept after the company announced its results on September 15. The plan to exit the investment in EPM paper was set for September 14 close. On September 10, there was a delay in the Securities Information Processor, or SIP, which is a system that processes stock trades, and it emitted data from 13:30 to 16:15. The entry price was 3.73, the last price was 3.805, and the high and low prices were 3.805 and 3.675 respectively, with no observed threshold hit. A calculation using Python, which is a programming language, showed a mark of +2.010724%, which is equal to 0.674218 R, and a gross distance to the target price of 3.89686, with a stop price of 3.61876 that did not change. The actual paper ADR, or Average Daily Range, was 1.1124, with frozen stress fees of 5 basis points, or bp, and a slip of 25 bp, resulting in a net target of 3.848493% and a loss of 3.562670%, with an RR, or risk-reward ratio, of 1.080227, which is less than 1.5. The conclusion is that the paper is ongoing, and there is no permission for entry or partial exit. The daily proxy, which is a measure of the investment's performance, is 1734/1928, which is unchanged. It is not recommended to convert minute observations to 15-minute venue validation. The validity of the investment is necessary, but the soundness is limited due to delayed emitted bars and cost assumptions, with no full corporate action audit or National Best Bid and Offer, or NBBO. A countercase, or opposite scenario, where the stock price goes up, may finish profitably, but a win would not fix the negative training. The sources of the data are https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&timeframe=1Min&feed=sip&adjustment=all and https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-schedules-fiscal-q4-and-full-year-2026.